Management and treatment of neuroendocrine tumors during the global COVID-19 pandemic - Experience of medical oncology department of hospital 1st November

#3268

Introduction: The current recommendations for management of neuroendocrine tumor diseases are still evolving, due to the limited experience on this issue. As the new coronavirus can be transmitted through breath droplets, by contact, there is no consensus of how this fact may affect the investigation and treatment of neuroendocrine tumor diseases.

Aim(s): There is no consensus of how this fact may affect the investigation and treatment of neuroendocrine tumor diseases.

Materials and methods: Using the GRADE system, published evidence was analysed to generate weighted statements for stage, site, acuity of presentation, and hospital setting to specify when surgery and chemotherapy should be pursued, the time and duration of oncologically acceptable delays, and when to utilize nonsurgical modalities to bridge the waiting period. An observational prospective study was conducted at the Medical Oncology Department of the Academic Hospital of Oran between March and October 2020, patients enrolled were aged >18 years, with untreated neuroendocrine with PCR or Thoracic CT. In all, 39 patients with advanced or metastatic CRC and 6 patients COVID-19-positive were enrolled in the study. The sex ratio was 1.8, with a mean (SD) age of 58.4 (3.5) years.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Bengueddach A, Kaid M, Kehili H, Tidjene A, Bereksi Reguig F,

Keywords: neuroendocrine, covid-19, treatment,